Gsk (GSK) Gains from Investment Securities (2009 - 2026)

Gsk (GSK) has 18 years of Gains from Investment Securities data on file, last reported at $48.3 million in Q3 2026.

• For the quarter ending Q3 2026, Gains from Investment Securities changed N/A year-over-year to $48.3 million; the trailing twelve-month figure through Sep 2026 stood at -$737.9 million (changed N/A YoY), and the FY2025 full-year result was $26.6 million, up 30.07% from the prior year.
• Gains from Investment Securities was $48.3 million for Q3 2026 at Gsk, up from $33.5 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $409.3 million in Q1 2022 to a low of -$888.6 million in Q4 2025.
• A 5-year average of -$73.6 million and a median of -$3.8 million in 2023 frame the typical range for Gains from Investment Securities.
• Across the five-year window, Gains from Investment Securities plunged 8553.58% in 2025 and soared 738.1% in 2026, its largest moves.
• Gsk's Gains from Investment Securities stood at -$635.7 million in 2022, then surged by 139.24% to $249.5 million in 2023, then sank by 104.12% to -$10.3 million in 2024, then plunged by 8553.58% to -$888.6 million in 2025, then soared by 105.44% to $48.3 million in 2026.
• Per Business Quant data, the three most recent Gains from Investment Securities figures were $48.3 million in Q3 2026, $33.5 million in Q2 2026, and $68.8 million in Q1 2026.